US S 3105, the Increase Support for Life‑saving Endocrine Transplantation (ISLET) Act, would change how human cadaveric islet cells for diabetes transplants are regulated so they are treated as organs rather than as drugs or lab‑grown tissue products. The bill amends the Public Health Service Act’s definition of “organ” to explicitly include “human cadaveric islets,” authorizing HRSA and the national organ transplant network to manage islet allocation and oversight under the same framework used for kidneys, pancreases, and other organs. It simultaneously prohibits the Department of Health and Human Services from regulating cadaveric islets as drugs under the Food, Drug, and Cosmetic Act, as biologics, or as human cells/tissue products (HCT/Ps), and directs the Secretary to update all relevant regulations within one year and report to Congress within six months on implementation progress. The goal is to remove FDA drug‑approval barriers that have effectively blocked clinical islet transplantation in the U.S., while placing these procedures in accredited organ‑transplant centers with existing safety and follow‑up systems.
Why It Matter to MAHA
The Make America Healthy Again Movement supports S 3105 because it expands access to a potentially life‑changing treatment for people with severe, brittle diabetes while keeping it inside the rigorous safety structure of the organ‑transplant system. By correcting the misclassification of cadaveric islets as “drugs” and shifting them to the organ‑transplant framework, the bill reduces red tape that has kept Americans from a therapy already available in other countries, aligning with MAHA’s goal of practical, evidence‑based tools—alongside nutrition and lifestyle—to prevent life‑threatening complications. Requiring transplants to occur in accredited programs with experience managing lifelong immunosuppression also fits MAHA’s emphasis on patient safety and careful risk‑benefit decision‑making for advanced interventions.